BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shim HJ, Kim DE, Hwang JE, Bae WK, Nam TK, Na KJ, Cho SH, Chung IJ. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol 2012;70:683-90. [PMID: 22932694 DOI: 10.1007/s00280-012-1962-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 van Ruler MAP, Peters FP, Slingerland M, Fiocco M, Grootenboers DARH, Vulink AJE, Marijnen CAM, Neelis KJ. Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Diseases of the Esophagus 2017;30:1-9. [DOI: 10.1093/dote/dow033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
2 Shim HJ, Shin MH, Kim HN, Kim JH, Hwang JE, Bae WK, Chung IJ, Cho SH. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy. Cancer Res Treat 2016;48:71-9. [PMID: 25989802 DOI: 10.4143/crt.2015.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
3 Chen X, Zhang W, Qian D, Guan Y, Wang Y, Zhang H, Er P, Yan C, Li Y, Ren X, Pang Q, Wang P. Chemoradiotherapy-Induced CD4+ and CD8+ T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma. Front Oncol 2019;9:73. [PMID: 30828566 DOI: 10.3389/fonc.2019.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhou XL, Yu CH, Wang WW, Ji FZ, Xiong YZ, Zhu WG, Tong YS. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2021;16:94. [PMID: 34039375 DOI: 10.1186/s13014-021-01821-6] [Reference Citation Analysis]
5 Liu S, Ren SN, Ding WX, Ge XL, Cao YD, Zhang S, Zhen FX, Sun XC. Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy. Ann Transl Med 2019;7:331. [PMID: 31475201 DOI: 10.21037/atm.2019.06.45] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sun X, Han S, Gu F, Lin G, Wang Z, Wang Y, Xu Y. A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma. J Cancer 2016;7:1066-73. [PMID: 27326249 DOI: 10.7150/jca.13547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
7 Song T, Liang X, Fang M, Wu S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther 2015;15:1157-69. [PMID: 26235427 DOI: 10.1586/14737140.2015.1074041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
8 Kim YH, Song SY, Shim HJ, Chung WK, Ahn SJ, Yoon MS, Jeong JU, Song JY, Nam TK. Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. Radiat Oncol J 2015;33:12-20. [PMID: 25874173 DOI: 10.3857/roj.2015.33.1.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Li M, Fu C, Zhang W, Huang W, Wang Z, Zhou T, Lin H, Li B. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 2016;89:20150476. [PMID: 26891913 DOI: 10.1259/bjr.20150476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
10 Hihara J, Hamai Y, Emi M, Murakami Y, Kenjo M, Nagata Y, Okada M. Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study. Dis Esophagus 2016;29:1115-20. [PMID: 26471962 DOI: 10.1111/dote.12433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 So B, Marcu LG, Olver I, Gowda R, Bezak E. Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas. Acta Oncologica 2017;56:899-908. [DOI: 10.1080/0284186x.2017.1307518] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Xia X, Liu Z, Cai B, Di X, Sun X, Ge X. A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma. Cancer Radiother 2021;25:39-44. [PMID: 33419607 DOI: 10.1016/j.canrad.2020.06.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liu Q, Xia Y, Chen Y, Zhang J, Deng J, Zhao K. A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence. Radiat Oncol 2020;15:75. [PMID: 32268925 DOI: 10.1186/s13014-020-01518-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Chen B, Deng M, Yang C, Dragomir MP, Zhao L, Bai K, Xi M, Hu Y, Zhu Y, Li Q. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis. Radiother Oncol 2021;158:191-9. [PMID: 33667583 DOI: 10.1016/j.radonc.2021.02.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Yoo EJ, Park JC, Kim EH, Park CH, Shim CN, Lee HJ, Chung HS, Lee H, Shin SK, Lee SK, Lee CG, Lee YC. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Digestive and Liver Disease 2014;46:846-53. [DOI: 10.1016/j.dld.2014.05.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
16 Ma H, Di Z, Wen J, Ke Y, Sun X, Ren J. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma. Japanese Journal of Clinical Oncology 2015;45:169-75. [DOI: 10.1093/jjco/hyu181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
17 Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu C, Sun NN, Li XJ, Zhai SC, Niu LJ. A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. PLoS One. 2015;10:e0128616. [PMID: 26046353 DOI: 10.1371/journal.pone.0128616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
18 Chen NB, Li QW, Li S, Guo SP, Wu YJ, Cheng ZJ, Li JB, Wang DQ, Liu FJ, Ai XL, Hu N, Qiu B, Liu H. Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021). Radiother Oncol. 2021;155:105-112. [PMID: 33144248 DOI: 10.1016/j.radonc.2020.10.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Ohnuma H, Sato Y, Hirakawa M, Okagawa Y, Osuga T, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Sagawa T, Hori M, Someya M, Nakata K, Sakata K, Takayama T, Kato J. A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. Int J Radiat Oncol Biol Phys 2015;93:382-90. [PMID: 26232855 DOI: 10.1016/j.ijrobp.2015.05.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]